Spe­cial re­port: Twen­ty ex­tra­or­di­nary women blaz­ing trails in bio­phar­ma R&D — Covid-19 and be­yond

In the sec­ond year of End­points News’  bud­ding tra­di­tion of high­light­ing women blaz­ing trails in bio­phar­ma R&D, we’ve seen a num­ber of firsts.

For the first time, the biggest sto­ry in R&D is al­so top of mind for a world anx­ious to end the most dev­as­tat­ing health cri­sis in decades. With its sweep­ing ef­fects, the Covid-19 pan­dem­ic is turn­ing the dai­ly rou­tines for many work­ing women up­side down, tak­ing a toll on not just their phys­i­cal and men­tal health, but al­so their ca­reer prospects. At the same time, the biotech in­dus­try is do­ing some se­ri­ous soul search­ing with a new score­card and plan for di­ver­si­ty and in­clu­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Principal

Alexandria Real Estate Equities

Cambridge, MA, USA